Articles & News

We are delighted to share that the ICM - Institut du Cancer de Montpellier was authorized by the French Data Protection Authority (CNIL) to conduct APAD-ECO study. The CNIL granted authorization to conduct a medico-economic study on the effects of physical activity in women treated for breast cancer on April, 19th. This groundbreaking study involves combining data from two clinical trials with that of the Caisse nationale de l’Assurance Maladie, covering the period from 2009 to 2022. The study aims to assess the long-term impacts of physical activity in patients who have undergone treatment for breast cancer. We are proud to have contributed to this project by providing the ICM - Institut du Cancer de Montpellier with a compliant Data Protection Impact Assessment (DPIA), a crucial step in obtaining CNIL approval.

From a data protection viewpoint, clinical trials encompass a range of tasks that can be daunting for clinical sponsors. The sheer volume of compliance activities required for clinical operations is staggering, including ICF reviews, vendor assessments, protocol reviews and CTIS statements, Data Protection Impact Assessments, Records of Processing, and more. Amidst this whirlwind of obligations, one requirement often emerges as an unexpected challenge for clinical sponsors without a presence in the EU or UK: appointing a data protection representative.‍

Here's our newest conversation with Brij Mohan Lal Srivastava, CEO and Co-founder of Nijta, a company at the forefront of AI in speech anonymization. The realm of voice is an emerging and fascinating area within the life sciences, and with every new domain, issues of privacy come to the forefront.